Yabao Pharmaceutical Group Co Ltd is a China-based company principally engaged in the research and development, production and sales of pharmaceutical products. The Company's main products include Chinese and Western medicine preparations, patches, active pharmaceutical ingredients and pharmaceutical packaging materials. The Company's products mainly involve pediatrics, adult medicines and health products. The Company sells its products under the brands of Yabao, Dinggui, Yabao Lishu and Yabao Weiyuan. The Company mainly operates its businesses in the domestic and overseas markets.

Employees

3,415

Sector

Pharmaceuticals

More about the company

Quotes

Date	Price	Change	Volume
03/08/26	CN¥6.910	+6.80%	57,204,979
31/07/26	CN¥6.470	+0.94%	16,771,669
30/07/26	CN¥6.410	-1.69%	16,237,907
29/07/26	CN¥6.520	+0.46%	12,455,743
28/07/26	CN¥6.490	-0.92%	10,317,443

End-of-day quote Shanghai S.E.

More quotes

Income Statement and Estimates

More financial data

End-of-day quote Shanghai S.E. Other stock markets 03/08/2026			5-day change	1st Jan Change
6.910 ^CNY	+6.80%		+7.80%	+6.47%

07-31	Shanxi Yabao Pharmaceutical Logistics Distribution Co., Ltd. announced that it has received CNY 50 million in funding from Yabao Pharmaceutical Group Co., Ltd	CI
07-31	Beijing Yabao Biopharmaceutical Co., Ltd. announced that it has received CNY 100 million in funding from Yabao Pharmaceutical Group Co., Ltd	CI

Market Cap	4.78B 709M 615M 573M 527M 994M 67.57B 1.01B 6.76B 2.65B 33.62B 2.66B 2.6B 112B	P/E 2024	18.1x	P/E 2025	14.2x
Enterprise Value	4B 593M 514M 479M 440M 831M 56.48B 847M 5.65B 2.21B 28.11B 2.23B 2.18B 93.22B	EV / Sales 2024	1.45x	EV / Sales 2025	1.65x
Free-Float	79.86%	Yield 2024	4.93%	Yield 2025	5.39%

07-31	Shanxi Yabao Pharmaceutical Logistics Distribution Co., Ltd. announced that it has received CNY 50 million in funding from Yabao Pharmaceutical Group Co., Ltd	CI
07-31	Beijing Yabao Biopharmaceutical Co., Ltd. announced that it has received CNY 100 million in funding from Yabao Pharmaceutical Group Co., Ltd	CI
07-31	Yabao Pharmaceutical Group Co., Ltd Reports Earnings Results for the Half Year Ended June 30, 2026	CI
07-31	Yabao Pharmaceutical Group Co., Ltd announces an Equity Buyback for CNY 200 million worth of its shares.	CI
07-30	Yabao Pharmaceutical Group Co., Ltd authorizes a Buyback Plan.	CI
05-25	Yabao Pharmaceutical Subsidiary Secures Chinese Regulatory Approval for High Cholesterol Tablets	MT
04-24	Yabao Pharmaceutical Group Co., Ltd Reports Earnings Results for the Full Year Ended December 31, 2025	CI
04-24	Yabao Pharmaceutical Group Co., Ltd Reports Earnings Results for the First Quarter Ended March 31, 2026	CI
12-21	Shanxi Tongxiang Times Technology Co., Ltd. completed the acquisition ofan additional 62% stake in Yabao Pharmaceutical Taiyuan Pharmaceutical Co., Ltd. from Yabao Pharmaceutical Group Co., Ltd.	CI
12-18	Yabao Pharma Gets Clinical Trial Nod for Pulmonary Arterial Hypertension Drug	MT
11-17	Tranche Update on Yabao Pharmaceutical Group Co., Ltd's Equity Buyback Plan announced on May 17, 2025.	CI
11-13	Yabao Pharmaceutical Group Co., Ltd's Equity Buyback announced on May 17, 2025, has closed with 8,000,000 shares, representing 1.14% for CNY 52.15 million.	CI
11-13	Yabao Pharmaceutical Obtains Registration for Children's Nutrition Product	MT

30/06/16	Yabao Pharmaceutical : Pharmaceuticals and LFB Biomedicaments Enter Into Strategic Partnership to Deliver VIALEBEX® (LFB’s Human Albumin) in China	BU
20/04/16	Yabao Pharmaceutical : Pharmaceuticals and Salus Pharma Announce Strategic Partnership for Generic Drugs	BU
12/01/16	Yabao Pharmaceuticals : and Sciecure Pharma Announce Strategic Partnership to Co-develop, Manufacture and Commercialize Generics for U.S. and China	BU
20/10/15	Yabao Pharmaceuticals : Enters Second Innovative Collaboration With Eli Lilly and Company to Develop Diabetes Treatment	BU
15/09/15	Yabao Pharmaceuticals : and Primary Peptides Announce Exclusive China Partnership	BU

Yabao Pharmaceutical Group Co., Ltd Share Price

Stocks

600351

CNE000001CM5

Pharmaceuticals

Valuation: Yabao Pharmaceutical Group Co., Ltd

Chart: Yabao Pharmaceutical Group Co., Ltd

Latest news : Yabao Pharmaceutical Group Co., Ltd

Press Releases: Yabao Pharmaceutical Group Co., Ltd

News in other languages: Yabao Pharmaceutical Group Co., Ltd

Quotes and Performance

Course Extremes

Managers and Directors: Yabao Pharmaceutical Group Co., Ltd

Generic Pharmaceuticals

Financials

Company Profile

Quotes

Income Statement and Estimates

1 day	+6.80%
1 week	+7.80%
Current month	+6.80%
1 month	+14.21%
3 months	-2.40%
6 months	+2.52%
Current year	+6.47%

1 week	6.33	6.97
1 month	6	6.97
Current year	5.6	7.19
1 year	5.6	8.68
3 years	4.94	9
5 years	4.94	11.9
10 years	4.5	11.9

Manager	Title	Age	Since
Wei Ren CEO	Chief Executive Officer	42	22/04/2019
Zhe Feng Zuo DFI	Director of Finance/CFO	54	16/05/2017
Peng Bo Ren PRN	Corporate Officer/Principal	53	10/03/2007

Director	Title	Age	Since
Wu Xian Ren CHM	Chairman	66	25/05/2005
Peng Bo Ren BRD	Director/Board Member	53	14/05/2014
Wei Ren BRD	Director/Board Member	42	22/04/2019

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
YABAO PHARMACEUTICAL GROUP CO., LTD	+6.80%	+7.80%	-13.08%	+0.88%	663M
SUN PHARMACEUTICAL INDUSTRIES LTD.	-1.36%	+1.15%	+20.48%	+72.96%	50.03B
OTSUKA HOLDINGS CO., LTD.	+3.60%	+3.09%	+54.20%	+116.82%	36.6B
CIPLA LIMITED	+0.08%	+4.52%	-1.89%	+26.20%	12.47B
ZYDUS LIFESCIENCES LIMITED	-0.51%	+1.11%	+18.12%	+78.33%	11.77B
KRKA, D. D.	-1.33%	-0.76%	+30.73%	+130.67%	9.04B
ONO PHARMACEUTICAL CO., LTD.	-1.95%	-4.00%	+42.44%	-12.71%	7.03B
GEDEON RICHTER	+1.10%	+2.58%	+14.71%	+34.12%	6.79B
GLENMARK PHARMACEUTICALS LIMITED	-0.17%	+1.73%	+7.84%	+185.66%	6.6B
SHENZHEN SALUBRIS PHARMACEUTICALS CO., LTD.	-0.24%	+3.14%	-35.41%	+8.71%	5.49B
Average	+0.60%	+1.63%	+13.81%	+64.16%	14.65B
Weighted average by Cap.	+0.29%	+1.34%	+25.41%	+80.36%

	2024	2025
Net sales	2.69B 398M 345M 322M 296M 558M 37.95B 569M 3.8B 1.49B 18.89B 1.5B 1.46B 62.64B	2.24B 332M 288M 268M 247M 465M 31.65B 474M 3.17B 1.24B 15.75B 1.25B 1.22B 52.24B
Net income	243M 35.97M 31.2M 29.08M 26.73M 50.43M 3.43B 51.4M 343M 134M 1.71B 135M 132M 5.66B	320M 47.43M 41.14M 38.35M 35.25M 66.49M 4.52B 67.77M 453M 177M 2.25B 178M 174M 7.46B
Net Debt	-483M -71.58M -62.07M -57.87M -53.19M -100M -6.82B -102M -683M -268M -3.4B -269M -263M -11.26B	-784M -116M -101M -93.99M -86.4M -163M -11.08B -166M -1.11B -435M -5.52B -437M -427M -18.29B